Graves' Ophthalmopathy - Pipeline Review, H1 2020
Graves' Ophthalmopathy - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy - Pipeline Review, H1 2020, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.
Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 3 and 1 respectively.
Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy - Pipeline Review, H1 2020, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.
Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 3 and 1 respectively.
Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves' Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves' Ophthalmopathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves' Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Graves' Ophthalmopathy - Overview
Graves' Ophthalmopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves' Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves' Ophthalmopathy - Companies Involved in Therapeutics Development
advanceCor GmbH
Chugai Pharmaceutical Co Ltd
Enceladus Pharmaceuticals BV
Genmab AS
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
Graves' Ophthalmopathy - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisolone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teprotumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves' Ophthalmopathy - Dormant Projects
Graves' Ophthalmopathy - Product Development Milestones
Featured News & Press Releases
Jun 01, 2020: Harbour BioMed receives Chinese regulatory approval of IND application to begin Seamless Phase 2/3 clinical trial of HBM9161 in Graves’ ophthalmopathy
May 14, 2020: New data on the pharmacokinetic profile of TEPEZZA (teprotumumab-trbw) reinforce the labeled dosing regimen, indicating a positive, consistent response to therapy
Mar 31, 2020: TEPEZZA (teprotumumab-trbw) significantly reduces proptosis (Eye Bulging), a key marker of thyroid eye disease, across patient subtypes
Mar 30, 2020: Immunovant announces positive clinical results from ongoing phase 2a proof-of-concept study of IMVT-1401, A novel investigational Anti-FcRn Antibody delivered by Subcutaneous Injection, in Thyroid Eye Disease
Feb 09, 2020: New treatment discovered for rare eye disease may prevent blindness
Jan 22, 2020: The New England Journal of Medicine publishes comprehensive data from phase 3 clinical trial (OPTIC) of TEPEZZA (teprotumumab-trbw) for thyroid eye disease
Jan 22, 2020: Horizon Therapeutics gets FDA approval for thyroid eye disease drug
Dec 13, 2019: FDA Advisory Committee votes unanimously to support the use of Teprotumumab for the treatment of Thyroid Eye Disease (TED)
Nov 25, 2019: Immunovant initiates dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in patients with Graves’ Ophthalmopathy (GO)
Nov 04, 2019: Clinical study data highlighting the impact of teprotumumab in patients with active thyroid eye disease to be presented During ACR Annual Meeting
Oct 24, 2019: New combined data from the phase 2 and phase 3 teprotumumab clinical trials to be presented during the American Thyroid Association Annual Meeting
Oct 11, 2019: New data from Teprotumumab phase 3 OPTIC study shows significantly reduced double vision and improved quality of life for people with active thyroid eye disease
Oct 08, 2019: New data insights from the phase 3 teprotumumab trial (OPTIC) to be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Sep 09, 2019: Horizon Therapeutics announces the FDA has granted priority review of the Teprotumumab Biologics License Application (BLA) for the treatment of active thyroid eye disease (TED)
Aug 19, 2019: American Journal of Ophthalmology (AJO) publishes review highlighting lack of treatments for active thyroid eye disease (TED)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Graves' Ophthalmopathy - Overview
Graves' Ophthalmopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves' Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves' Ophthalmopathy - Companies Involved in Therapeutics Development
advanceCor GmbH
Chugai Pharmaceutical Co Ltd
Enceladus Pharmaceuticals BV
Genmab AS
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
Graves' Ophthalmopathy - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisolone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teprotumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves' Ophthalmopathy - Dormant Projects
Graves' Ophthalmopathy - Product Development Milestones
Featured News & Press Releases
Jun 01, 2020: Harbour BioMed receives Chinese regulatory approval of IND application to begin Seamless Phase 2/3 clinical trial of HBM9161 in Graves’ ophthalmopathy
May 14, 2020: New data on the pharmacokinetic profile of TEPEZZA (teprotumumab-trbw) reinforce the labeled dosing regimen, indicating a positive, consistent response to therapy
Mar 31, 2020: TEPEZZA (teprotumumab-trbw) significantly reduces proptosis (Eye Bulging), a key marker of thyroid eye disease, across patient subtypes
Mar 30, 2020: Immunovant announces positive clinical results from ongoing phase 2a proof-of-concept study of IMVT-1401, A novel investigational Anti-FcRn Antibody delivered by Subcutaneous Injection, in Thyroid Eye Disease
Feb 09, 2020: New treatment discovered for rare eye disease may prevent blindness
Jan 22, 2020: The New England Journal of Medicine publishes comprehensive data from phase 3 clinical trial (OPTIC) of TEPEZZA (teprotumumab-trbw) for thyroid eye disease
Jan 22, 2020: Horizon Therapeutics gets FDA approval for thyroid eye disease drug
Dec 13, 2019: FDA Advisory Committee votes unanimously to support the use of Teprotumumab for the treatment of Thyroid Eye Disease (TED)
Nov 25, 2019: Immunovant initiates dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in patients with Graves’ Ophthalmopathy (GO)
Nov 04, 2019: Clinical study data highlighting the impact of teprotumumab in patients with active thyroid eye disease to be presented During ACR Annual Meeting
Oct 24, 2019: New combined data from the phase 2 and phase 3 teprotumumab clinical trials to be presented during the American Thyroid Association Annual Meeting
Oct 11, 2019: New data from Teprotumumab phase 3 OPTIC study shows significantly reduced double vision and improved quality of life for people with active thyroid eye disease
Oct 08, 2019: New data insights from the phase 3 teprotumumab trial (OPTIC) to be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Sep 09, 2019: Horizon Therapeutics announces the FDA has granted priority review of the Teprotumumab Biologics License Application (BLA) for the treatment of active thyroid eye disease (TED)
Aug 19, 2019: American Journal of Ophthalmology (AJO) publishes review highlighting lack of treatments for active thyroid eye disease (TED)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Graves' Ophthalmopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Graves' Ophthalmopathy - Pipeline by advanceCor GmbH, H1 2020
Graves' Ophthalmopathy - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Graves' Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, H1 2020
Graves' Ophthalmopathy - Pipeline by Genmab AS, H1 2020
Graves' Ophthalmopathy - Pipeline by GlaxoSmithKline Plc, H1 2020
Graves' Ophthalmopathy - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Graves' Ophthalmopathy - Dormant Projects, H1 2020
Number of Products under Development for Graves' Ophthalmopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Graves' Ophthalmopathy - Pipeline by advanceCor GmbH, H1 2020
Graves' Ophthalmopathy - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Graves' Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, H1 2020
Graves' Ophthalmopathy - Pipeline by Genmab AS, H1 2020
Graves' Ophthalmopathy - Pipeline by GlaxoSmithKline Plc, H1 2020
Graves' Ophthalmopathy - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Graves' Ophthalmopathy - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Graves' Ophthalmopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
advanceCor GmbH
Chugai Pharmaceutical Co Ltd
Enceladus Pharmaceuticals BV
Genmab AS
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
Number of Products under Development for Graves' Ophthalmopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
advanceCor GmbH
Chugai Pharmaceutical Co Ltd
Enceladus Pharmaceuticals BV
Genmab AS
GlaxoSmithKline Plc
HanAll Biopharma Co Ltd
